0.7785

3.99% 0.0299

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $0.7785, with a volume of 44,946. It is up +3.99% in the last 24 hours and down -4.68% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$0.7486

Open:

$0.75

24h Volume:

44,946

Relative Volume:

0.22

Market Cap:

$42.44M

Revenue:

$76.19M

Net Income/Loss:

$-1.61M

P/E Ratio:

77.85

EPS:

0.01

Net Cash Flow:

$28.98M

1W Performance:

-1.21%

1M Performance:

-4.68%

6M Performance:

-43.18%

1Y Performance:

-53.10%

1-Day Range:

$0.75

$0.7785

1-Week Range:

$0.73

$0.80

52-Week Range:

$0.73

$1.89

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2024-11-11

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	0.7785	42.44M	76.19M	-1.61M	28.98M	0.01
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Mar 11, 2025

Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com

Mar 11, 2025

Mar 07, 2025

Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

Mar 07, 2025

Mar 06, 2025

Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025

Mar 05, 2025

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025

Mar 04, 2025

Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart

Mar 04, 2025

Mar 01, 2025

Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India

Mar 01, 2025

Feb 25, 2025

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 25, 2025

UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 25, 2025

Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail

Feb 25, 2025

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 25, 2025

Rare Disease Biotech Spero Therapeutics Takes Stage at Major TD Cowen Healthcare Conference - StockTitan

Feb 25, 2025

Can Spero Therapeutics' Rare Disease Pipeline Impress Investors at Major Healthcare Conference? - StockTitan

Feb 25, 2025

Feb 07, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Feb 07, 2025

Feb 06, 2025

Spero therapeutics CFO sells $16,137 in stock By Investing.com - Investing.com Nigeria

Feb 06, 2025